FFO
IBRX icon

Fortitude Family Office’s ImmunityBio IBRX Stock Holding History

Fortitude Family Office’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38K Buy
157
+43
+38% +$325 ﹤0.01% 1629
2026
Q1 		$874 Buy
114
+80
+235% +$548 ﹤0.01% 1543
2025
Q4 		$67 Sell
34
-10
-23% -$23 ﹤0.01% 1902
2025
Q3 		$108 Hold
44
– – ﹤0.01% 1956
2025
Q2 		$116 Buy
+44
New +$118 ﹤0.01% 1998
2024
Q4 		– Sell
-95
Closed -$353 – 1341
2024
Q3 		$353 Buy
+95
New +$440 ﹤0.01% 1178

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fortitude Family Office's IBRX Position: Q2 2026 in Review

Fortitude Family Office increased its ImmunityBio (IBRX) stake by 38% in Q2 2026, buying an estimated $325 and bringing the position to 157 shares worth $1.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

Fortitude Family Office first reported a position in IBRX in Q3 2024 and has held it in 6 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Fortitude Family Office held 157 shares of ImmunityBio worth $1.38K as of Q2 2026.
  • Fortitude Family Office bought 43 ImmunityBio shares in Q2 2026, an estimated $325.
  • ImmunityBio made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1629 holding.
  • Fortitude Family Office first reported a position in ImmunityBio in Q3 2024 and has held it in 6 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.